Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Published byNazar Cavus Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the."— Presentation transcript:

1 Figure 1 Design of trials included in individual patient data meta-analysis.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Primary composite endpoint of cardiac death or myocardial infarction. The cumulative incidence of the primary ... Figure 2 Primary composite endpoint of cardiac death or myocardial infarction. The cumulative incidence of the primary endpoint of cardiac death or myocardial infarction was significantly reduced in subjects randomized to fractional flow reserve-guided percutaneous coronary intervention compared with medical therapy alone. Dashed lines are crude time-to-event curves and solid lines are fitted cumulative incidence curves as predicted from a mixed effects flexible parametric model. Only the fitted curves should be used for inferences about the treatment effect. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 Subgroup analyses of primary composite endpoint of cardiac death or myocardial infarction. Pre-specified ... Figure 3 Subgroup analyses of primary composite endpoint of cardiac death or myocardial infarction. Pre-specified subgroup analyses of the primary outcome are shown according to clinical presentation (stable coronary artery disease vs. acute coronary syndrome) and fractional flow reserve status (patients with at least one stable coronary lesion with a positive fractional flow reserve of ≤0.80 vs. patients with only lesions with a negative fractional flow reserve of >0.80). The Post hoc subgroup analyses of the primary endpoint specified are shown according to age (>60 years or ≤60 years), sex, diabetes status, previous myocardial infarction, and smoking. CAD, coronary artery disease; FFR, fractional flow reserve; HR, hazard ratio; MT, medical therapy; PCI, percutaneous coronary intervention. P-values for interaction are for within-trial interaction unless indicated otherwise. *P-value for interaction is for across-trial interaction. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4 Landmark analyses of primary composite endpoint and its components. The hazard ratios of the primary ... Figure 4 Landmark analyses of primary composite endpoint and its components. The hazard ratios of the primary composite outcome of cardiac death or myocardial infarction and of components of the primary composite outcome shown according to the time from randomization (7 days or less vs. 8 days or more). The solid boxes represent hazard ratios for 7 days or less after randomization, the open boxes represent hazard ratios for 8 days or more from randomization. Arrows indicate that the ends of the confidence interval are either less than 0.4 or more than 5. FFR, fractional flow reserve; HR, hazard ratio; PCI, percutaneous coronary intervention. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, Volume 40, Issue 2, 28 December 2018, Pages 180–186, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Figure 1 Ischaemic endpoints

Figure 1 Ischaemic endpoints
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 1 Study flow chart.

Figure 1 Study flow chart.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

Similar presentations

Ads by Google